MJA InSight
MJA Careers

The dilemmas of prostate cancer screening

George G Miklos
Med J Aust 2013; 199 (9): 582.

To the Editor: Recent articles in the Journal reflect the continuing polarisation of the debate on prostate-specific antigen-based screening and the extent to which major clinical trials reveal whether lives are saved by intervention and/or watchful waiting.1,2All clinical trials have limitations, and the ERSPC (European Randomized Study of Screening for Pro

George G Miklos, Director
Secure Genetics, Sydney, NSW.
Article References: 
Reference Text: 
Hugosson J, Carlsson SV. The dilemmas of prostate cancer screening. Med J Aust 2013; 198: 528-529.
Reference Order: 
Reference Text: 
Del Mar CB, Glasziou PP, Hirst GH, et al. Should we screen for prostate cancer? A re-examination of the evidence. Med J Aust 2013; 198: 525-527.
Reference Order: 
Reference Text: 
Schröder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981-990.
Reference Order: 
PubMed ID: 
Reference Text: 
Andriole GL, Crawford ED, Grubb RL 3rd, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012; 104: 125-132.
Reference Order: 
PubMed ID: 

The full contents of this page are only available to subscribers.